Evaluate the adequacy of penal provisions under the Drugs and Cosmetics Act, 1940 in deterring large-scale spurious drug trade.

A "spurious drug" under the Drugs and Cosmetics Act, 1940 is one manufactured under another drug's name, or an imitation or substitute passed off as genuine [2]. With organised rackets moving consignments worth crores into hospital supply chains, the Act's penal architecture — though substantial on paper — is proving an uneven deterrent against trade at scale.

Strengths of the existing penal framework

• Graded punishment: Section 27 prescribes stringent imprisonment and fine for manufacture or sale of spurious drugs, with the harshest terms reserved for cases causing death or grievous hurt, recognising varying culpability [2].
• Cognisable and non-bailable character of major offences, backed by Special Courts for trial, signals legislative seriousness [2].
• Deterrence in practice: joint CDSCO–State enforcement has yielded real prosecutions, as in the Kolkata seizure of suspected spurious anti-cancer and anti-diabetic drugs valued at ₹6.60 crore, with the proprietor arrested and remanded [1].
• Administrative penalties supplement criminal ones — risk-based inspections since December 2022 covered 905 units and generated 694 actions, including Stop Production Orders and licence cancellations [3].

Inadequacies against organised, large-scale trade

• Profit–penalty mismatch: baseline terms for ordinary spurious-drug offences are modest relative to crore-scale illicit margins, weakening deterrence at the top of the network [2].
• Proving intent and "grievous hurt" links the harshest sentences to patient-level harm that is rarely traceable, so kingpins often face lesser heads of charge.
• Enforcement, not statute, is the weak link: licensing and inspection rest largely with State Drugs Controllers, producing uneven capacity, low conviction rates and delayed trials despite Special Courts [3].
• Unlicensed units and repackaging of expired stock expose gaps in supply-chain traceability, which penal law alone cannot close.

The provisions are adequate in severity but inadequate in reach — punishment is stiff where harm is proven, yet seldom reaches organised financiers. Strengthening State regulatory capacity, mandatory track-and-trace barcoding, time-bound Special Court trials and asset forfeiture would convert statutory severity into real deterrence, advancing the Article 21 guarantee of health and SDG-3.